Journal of Scientific Dentistry

Register      Login

VOLUME 10 , ISSUE 2 ( July-December, 2020 ) > List of Articles


Management of Oral Submucous Fibrosis with Intralesional Injection of Hyaluronidase and Dexamethasone: A Case Report

Thamizhp P Guna, Ramanujam Sathyanarayanan, Rilna Pilavullathil, Nithin J Jude, Raghu Kumaravel, C Selvakumar, S Bharathi

Citation Information : Guna TP, Sathyanarayanan R, Pilavullathil R, Jude NJ, Kumaravel R, Selvakumar C, Bharathi S. Management of Oral Submucous Fibrosis with Intralesional Injection of Hyaluronidase and Dexamethasone: A Case Report. 2020; 10 (2):41-42.

DOI: 10.5005/jp-journals-10083-0924

License: CC BY-NC 4.0

Published Online: 01-03-2021

Copyright Statement:  Copyright © 2020; The Author(s).


Oral submucous fibrosis (OSMF) is a chronic premalignant condition more common. It occurs mostly due to betel quid chewing. The characteristic feature of OSMF is the progressive hyalinization of the submucosa. Resistance and progression are the factors that attributes to its nature of affecting the entire mucosa. It causes reduction in mouth opening gradually, which can extend to the pharynx. It is a potentially malignant condition causing fibrosis of the connective tissues. Although medical treatment provides only symptomatic, optimal doses of injection with corticosteroids, hyaluronidase, and local anesthesia locally produced significant reduction in the clinical symptoms. This article is to report a case of OSMF, which was treated similarly and had better results than either agents used individually.

  1. Intralesional injections in oral submucous fibrosis - a series of case reports. J Med, Rad, Pathol Surg 2018;5(5):23–26. DOI: 10.15713/ins.jmrps.145.
  2. Management of oral submucous fibrosis with injection of hyaluronidase and dexamethasone in grade III oral submucous fibrosis: a retrospective study. J Int Oral Health 2015;7(8):82–85.
  3. Drug treatment of oral sub mucous fibrosis – a review. Int J Contempor Med Res 2016;3(4):996–998.
  4. Oral submucous fibrosis: Newer proposed classification with critical updates in pathogenesis and management strategies. Natl J Maxillofac Surg 2017;8(2):89–94. DOI: 10.4103/njms.NJMS_32_17.
  5. Early stage oral submucous fibrosis is characterized by increased vascularity as opposed to advanced stages. J Clin Diagnos Res 2017;11(5):92–96. DOI: 10.7860/JCDR/2017/25800.9948.
  6. Management of oral submucous fibrosis: a conservative approach. J Oral Maxillofac Surg 1991;49(8):788–791. DOI: 10.1016/0278-2391(91)90002-4.
  7. Intraoral injection of hydrocortisone and placental extract in oral submucous fibrosis. Indian J Otolaryngol 1978;30(2):103.
  8. Drug treatment of oral submucous fibrosis: a review of the literature. J Oral Maxillofac Surg 2009;67(7):1510–1515. DOI: 10.1016/j.joms.2008.12.056.
  9. Role of oxidative stress and antioxidants in aetiopathogenesis and management of oral submucous fibrosis. Indian J Clin Biochem 2004;19(1):138. DOI: 10.1007/BF02872409.
  10. Injection placentrex in the management of oral submucous fibrosis. Int J Mod Sci Eng Technol 2015;2(1):23–30.
  11. Oral Submucous fibrosis: a review of the current management and possible directions for novel therapies. Oral Surg, Oral Med, Oral Pathol Oral Radiol 2016;122(2):232–241. DOI: 10.1016/j.oooo.2016.02.020.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.